Vicente Rodriguez, MD
Pulmonary Disease · Fort Wayne, INNPI 1407832694
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (41.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Intuitive Surgical at 48.9% of the total. 2025 is the largest year on record at $5,650, more than ten times the $448 reported in 2019.
Across 180 payments — averaging $54.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- Inspire Medical Systems, Inc.$2K
- AstraZeneca$850
- GSK$448
- Boehringer Ingelheim$213
- Electromed, Inc.$207
- plus $1K from 27 others
Across 6 payments — averaging $5448.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$32K
- Apellis Pharmaceuticals, Inc.$1K
What the payments were for
- Travel & lodging$1,77818%
- Food & beverage$4,01341%
- Education$4,07441%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $4,821 |
| Inspire Medical Systems, Inc. | 24 | $1,836 |
| AstraZeneca | 34 | $850 |
| GSK | 35 | $448 |
| Boehringer Ingelheim | 7 | $213 |
| Electromed, Inc. | 17 | $207 |
| Grifols USA, LLC | 7 | $153 |
| ZOLL Respicardia, Inc. | 1 | $136 |
| Olympus America Inc. | 3 | $127 |
| Medical Device Business Services, Inc. | 1 | $121 |
| Regeneron Healthcare Solutions, Inc. | 5 | $119 |
| Jazz Pharmaceuticals Inc. | 3 | $77 |
| Merck | 4 | $71 |
| Mylan Specialty L.p. | 4 | $65 |
| Inogen, Inc. | 3 | $56 |
| Genentech USA, Inc. | 1 | $48 |
| Abiomed | 2 | $47 |
| Abbott | 2 | $45 |
| Harmony Biosciences LLC | 2 | $42 |
| Actelion Pharmaceuticals US, Inc. | 2 | $41 |
| Bayer | 2 | $37 |
| Mallinckrodt Hospital Products Inc. | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Boston Scientific | 1 | $32 |
| Baxter Healthcare | 1 | $32 |
| Sanofi | 2 | $29 |
| Johnson & Johnson | 1 | $26 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| United Therapeutics Corporation | 1 | $22 |
| Insmed, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,865 in reported general payments places this provider in the 75th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 29 | $377,301 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 348 | $316,390 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $134,012 |
| Dupixent PenDupilumab | 20 | $101,114 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 78 | $67,062 |
| Spiriva RespimatTiotropium Bromide | 64 | $40,910 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $29,971 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $22,653 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 28 | $21,972 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $20,084 |
| SymbicortBudesonide/Formoterol Fumarate | 56 | $19,801 |
| EliquisApixaban | 26 | $18,306 |
| Roflumilast | 185 | $13,525 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 72 | $8,175 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 223 | $8,090 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $213 | $460,266138 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $448 | $369,015419 claims |
| Grifols USA, LLCProlastin C | $153 | $134,01211 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $850 | $86,863134 claims |
| MerckDulera | $71 | $5,83716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Fort Wayne
- Daria LeeFort Wayne$69K
- Abhishek BiswasFort Wayne$30K
- Vatche IsrabianFort Wayne$22K
- Shivu KaushikFort Wayne$10K
- Manuel MartinezFort Wayne$9K
- Eric PetersonFort Wayne$9K
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Ajay DeshpandeTerre Haute$304K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.